Therapeutische Angiogenese mittels Gen- und Stammzellentherapie bei der peripheren arteriellen Verschlusskrankheit

Zusammenfassung

Die bisher weltweit größte Angiogenese-Gentherapie-Studie mit 525 Patienten mit kritischer Beinischämie, die mit dem nicht viralen Gen für den Fibroblasten-Wachstumsfaktor 1 (NV1FGF) oder Plazebo behandelt wurden, war bezüglich aller Endpunkte negativ. Aber auch bezüglich einer Stammzellen- bzw. Progenitorzell-Therapie für die periphere arterielle Verschlusskrankheit gibt es augenblicklich noch keine gesicherten Daten, die einen klinischen Benefit belegen. Daten aus großen randomisierten placebokontrollierten Studien stehen noch aus.

Abstract

The world-wide largest angiogenesis gene therapy trial in 525 patients suffering from critical limb ischemia and treated with the non-viral gene construct for fibroblast growth factor (NV1FGF) or placebo was negative for all endpoints. Also, stem cell or progenitor cell therapy did no reveal clinical benefit in patients with peripheral artery disease. Data from large randomized placebo-controlled are still not available.

Angiogenese - Stammzelltherapie - periphere arterielle Verschlusskrankheit

angiogenesis - stem cell therapy - peripheral artery disease

Literatur

• 1 Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner J M. Isolation of putative progenitor endothelial cells for angiogenesis.  Science. 1997;  275 964-967
• 2 Creager M, Olin J W, Belch J. et al .A randomized, double-blind, placebo-controlled, parallel group study of ad2/hypoxia inducible factor (HIF-1a/vp16) in patients with intermittent claudication. Orlando, Florida: American College of Cardiology (ACC) 58th Annual Scientific Session; March 29 – 31, 2009
• 3 Isner J M, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes J F. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb.  Lancet. 1996;  348 370-374
• 4 Kusumanto Y H, van Weel V, Mulder N H, Smit A J, van den Dungen J J, Hooymans J M, Sluiter W J, Tio R A, Quax P H, Gans R O, Dullaart R P, Hospers G A. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial.  Hum Gene Ther. 2006;  17 683-691
• 5 Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal.  Thromb Haemost. 2010;  103 696-709
• 6 Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E, Yla-Herttuala S. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study.  Mol Ther. 2002;  2 127-133
• 7 Nikol S, Baumgartner I, Van Belle E, Diehm C, Visoná A, Capogrossi M C, Ferreira-Maldent N, Gallino A, Wyatt M G, Wijesinghe L D, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, Meyer F TALISMAN 201 investigators. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia.  Mol Ther. 2008;  16 972-978
• 8 Powell R J, Goodney P, Mendelsohn F O, Moen E K, Annex B H. HGF-0205 Trial Investigators . Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF- 0205 trial.  J Vasc Surg. 2010;  52 1525-1530
• 9 Rajagopalan S, Mohler 3rd E R, Lederman R J, Mendelsohn F O, Saucedo J F, Goldman C K, Blebea J, Macko J, Kessler P D, Rasmussen H S, Annex B H. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.  Circulation. 2003;  108 1933-1938
• 10 Sprengers R W, Moll F L, Verhaar M C. Stem cell therapy in PAD.  Eur J Vasc Endovasc Surg. 2010;  39 Suppl 1 S38-43
• 11 Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T. Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators . Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.  Lancet. 2002;  360 427-435
• 12 US National Institutes of Health .A Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose-selection study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 in patients with intermittent claudication. http://clinicaltrials.gov/ ct2/show/NCT00117650?term= WALK+HIF-1+alpha&rank=1 (letzter Zugriff 3.3.2011)
• 13 Walter D. PROVASA-Studie, Präsentation im Rahmen des Leipzig Interventional Course- LINC- 2010. 
• 14 Hiatt W R, Baumgartner I, Nikol S, Van Belle E, Driver V, Norgren L, Belch J. (TAMARIS steering committee) .http://www.slideshare.net/alizotte/aha-tamaris (letzter Zugriff 3.3.2011)